{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:47:59Z","timestamp":1793998079703,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11899-023-00689-5","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T11:51:23Z","timestamp":1676029883000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-0230","authenticated-orcid":false,"given":"Ellin","family":"Berman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"issue":"6","key":"689_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffman","year":"2015","unstructured":"Hoffman VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29(6):1336\u201343.","journal-title":"Leukemia"},{"key":"689_CR2","unstructured":"Novartis (Gleevec): Highlights of prescribing information. https:\/\/www.pharma.us.novratis.com\/sites\/www.pharma.us.novartis.com\/files\/gleevec_tabs.pdf"},{"key":"689_CR3","doi-asserted-by":"crossref","unstructured":"Cortes J, Abruzzese E, Chelysheva E at al. The impact of dasatinib on pregnancy outcome. Am J Hematol 2015: 90: 1111\u20131114.","DOI":"10.1002\/ajh.24186"},{"key":"689_CR4","unstructured":"Bristol-Meyers Squibb Company: Sprycel (dasatinib) [prescribing information], https:\/\/packageinserts.bms.com\/pi_pisprycel.pdf"},{"key":"689_CR5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1200\/JCO.2017.77.2574","volume":"6","author":"E Berman","year":"2018","unstructured":"Berman E, Druker B, Burwick R. Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy. J Clin Oncol. 2018;6:1250\u20136.","journal-title":"J Clin Oncol"},{"issue":"7","key":"689_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3109\/14767058.2014.932765","volume":"28","author":"R Sivansankar","year":"2015","unstructured":"Sivansankar R, Kumar RA, Baraz R, et al. The white cell count in pregnancy and labor: a reference range. J Maternal Fetal Neonatal Med. 2015;28(7):790\u20132.","journal-title":"J Maternal Fetal Neonatal Med"},{"issue":"6","key":"689_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcla.22150","volume":"31","author":"A Li","year":"2017","unstructured":"Li A, Yang S, Zhang J, et al. Establishment of reference intervals for complete blood count parameters during normal pregnancy in Beijng. J Clin Lab Anal. 2017;31(6):1\u20137.","journal-title":"J Clin Lab Anal"},{"key":"689_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ajmg.10781","volume":"112","author":"LB Holmes","year":"2002","unstructured":"Holmes LB. Teratogen -induced limb defects. Am J Med Genet. 2002;112:297\u2013303.","journal-title":"Am J Med Genet"},{"key":"689_CR9","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00018-010-0619-9","volume":"68","author":"T Ito","year":"2011","unstructured":"Ito T, Ando H, Handa H. Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci. 2011;68:1569\u201379.","journal-title":"Cell Mol Life Sci"},{"key":"689_CR10","doi-asserted-by":"publisher","first-page":"H632","DOI":"10.1152\/ajpheart.00641.2016","volume":"312","author":"M Midgett","year":"2017","unstructured":"Midgett M, Thornburg K, Rugonyi S. Blood flow patterns underlie developmental heart defects. Am J Physiol Circ Physiol. 2017;312:H632\u201342.","journal-title":"Am J Physiol Circ Physiol"},{"key":"689_CR11","unstructured":"Chaubes, Murphy ML. The effects of hydroxyurea and related compounds on the rat fetus. Cancer Res 1966: 20: 1448\u20131457."},{"key":"689_CR12","unstructured":"Schwartz J, Winters JL, Padmanabhan A et al. Guidelines for the use of therapeutic apheresis in clinical practice- evidence based approach from the Writing Committee of the American Society of Apheresis: the sixth special issue, J Clin Apher 2015: 289\u2013292."},{"key":"689_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/trf.14448","volume":"58","author":"EN Staley","year":"2018","unstructured":"Staley EN, Simmons SC, Feldman AZ, et al. Management of chronic myeloid leukemia in setting of pregnancy: when is leukocytapheresis appropriate? A case study and review of the literature. Transfusion. 2018;58:546\u2013460.","journal-title":"Transfusion"},{"key":"689_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/AOG.0000000000001972","volume":"129","author":"RM Burwick","year":"2017","unstructured":"Burwick RM, Kuo K, Brewer D, et al. Maternal fetal and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy. Obstet Gynecol. 2017;129:831\u20134.","journal-title":"Obstet Gynecol"},{"key":"689_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/jca.21410","volume":"31","author":"P Galera","year":"2016","unstructured":"Galera P, Haynes S, Sulmasy P, et al. Physiologic measurements corroborate symptomatic improvement after therapeutic leukapheresis in a pregnancy woman with chronic myelogenous leukemia. J Clin Apheresis. 2016;31:393\u20137.","journal-title":"J Clin Apheresis"},{"issue":"Suppl 2","key":"689_CR16","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1007\/s00277-015-2317-z","volume":"94","author":"R Palani","year":"2015","unstructured":"Palani R, Milojkovic D, Apperley J. managing pregnancy in chronic myeloid leukemia. Ann Hematol. 2015;94(Suppl 2):S167-176.","journal-title":"Ann Hematol"},{"key":"689_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.reprotox.2011.11.003","volume":"33","author":"P YazdaniBrojeni","year":"2012","unstructured":"YazdaniBrojeni P, Matok I, Garcia Bornissen F, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012;33:265\u20138.","journal-title":"Reprod Toxicol"},{"key":"689_CR18","doi-asserted-by":"crossref","unstructured":"Beauvard Y, Radia D, Cargo C et al. Pegylated interferon alpha-1 for essential thrombocythemia during pregnancy: outcome and safety. Haematologica 2016: 101: 2182-2186 Reviews use of interferon alpha in large series of women with ET who require therapy during pregnancy.","DOI":"10.3324\/haematol.2015.139691"},{"key":"689_CR19","first-page":"7","volume":"20","author":"JC Pons","year":"2005","unstructured":"Pons JC, Lebron E, Frydman R, et al. Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther. 2005;20:7\u201310.","journal-title":"Fetal Diagn Ther"},{"key":"689_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/sj.leu.2402168","volume":"15","author":"C Thauvin-Robinet","year":"2001","unstructured":"Thauvin-Robinet C, Maingueneau C, Robert E, et al. Exposure to hydroxyurea during pregnancy: A case series. Leukemia. 2001;15:1309\u201311.","journal-title":"Leukemia"},{"key":"689_CR21","doi-asserted-by":"crossref","unstructured":"Chelysheva E, Turkina A, Rea D et al. Pregnancy outcome in female patients with chronic myeloid leukemia worldwide: analysis of 305 cases of the European Leukemia Net Registry. HemaSphere2019: 3 (Suppl. 1): 395\u2013396.","DOI":"10.1097\/01.HS9.0000561804.14876.ab"},{"issue":"Supplement","key":"689_CR22","first-page":"2881","volume":"130","author":"R Assi","year":"2017","unstructured":"Assi R, Kantarjian HM, Keating MJ. Management of chronic myeloid leukemia (CML) during pregnancy among patients (pts) treated with a tyrosine kinase inhibitor (TKI): a single center experience. Blood. 2017;130(Supplement):2881.","journal-title":"Blood"},{"key":"689_CR23","unstructured":"https:\/\/ww.FDA.gov.drugs. labeling- information-drug. FR Doc 2014: 28241. Filed 12\/3 2014. Content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling."},{"key":"689_CR24","doi-asserted-by":"crossref","unstructured":"Abruzzese A, Mauro M, Apperley J et al. Tyrosine kinase inhibitors and pregnancy in chronic myeloid ;leukemia: opinion, evidence and recommendations. Ther Adv Hematol 2020: 11: 1-13 Excellent review of issues confronting health care providers taking care of women during pregnancy.","DOI":"10.1177\/2040620720966120"},{"key":"689_CR25","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505\u20138.","journal-title":"Blood"},{"key":"689_CR26","doi-asserted-by":"crossref","unstructured":"Ali R, Ozkalemkas F, Kimya et al. Imatinib use during pregnancy and breast feeding: case report and review of the literature. Arch Genecol Obstet 2009: 280: 169\u2013175.","DOI":"10.1007\/s00404-008-0861-7"},{"key":"689_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00404-007-0547-6","volume":"278","author":"EE Buyukbayrak","year":"2008","unstructured":"Buyukbayrak EE, Ergen B, Karsidag YK, et al. Pregnancy complicated by chronic myelogenous leukemia (CML) successfully treated with imatinib: a case report. Arch Gynecol Obstet. 2008;278:161\u20133.","journal-title":"Arch Gynecol Obstet"},{"key":"689_CR28","doi-asserted-by":"crossref","unstructured":"Russell MA, Carpenter MW, Akhtar MS et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord, placenta and breast milk. J Perinatatol 2007: 241\u2013243.","DOI":"10.1038\/sj.jp.7211665"},{"key":"689_CR29","unstructured":"Bristol-Meyers Squibb Company: Sprycel (dasatinib) [prescribing information], https:\/\/packageinserts.bms.com\/pi_pisprycel.pdf"},{"key":"689_CR30","doi-asserted-by":"publisher","unstructured":"Zhao HF et al (Article in Chinese) Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14: 40(121): 986\u2013989. Chinese.\u00a0https:\/\/doi.org\/10.2760\/cma.i.issn.0253-2727.2019.12.003.","DOI":"10.2760\/cma.i.issn.0253-2727.2019.12.003"},{"key":"689_CR31","doi-asserted-by":"crossref","unstructured":"Cortes JE, Ganbacorti-Passerini C, Deininger M, et al. Pregnancy outcomes in patients treated with bosutinib. Int J Hematol Oncol 2929: 9(2), IJH25.","DOI":"10.2217\/ijh-2020-0004"},{"key":"689_CR32","unstructured":"Iclusig (ponatinib) tablets. Food and Drug Administration. https:\/\/www.accessdata.fda.gov"},{"key":"689_CR33","unstructured":"Scemblix (asiminib) tablets. https:\/\/www.hcp.novartis.com"},{"key":"689_CR34","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1056\/NEJMcp1307341","volume":"373","author":"GL Schattman","year":"2015","unstructured":"Schattman GL. Cryopreservation of oocytes. New Engl J Med. 2015;373:1755\u201360.","journal-title":"New Engl J Med"},{"key":"689_CR35","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Brummendorf","year":"2022","unstructured":"Brummendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results for the BFORE trial. Leukemia. 2022;36:1825\u201333.","journal-title":"Leukemia"},{"key":"689_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Brummendorf","year":"2015","unstructured":"Brummendorf TH, Cortes JE, de Souza A, et al. Bosutinib versus imatinib in newly diagnosed chronic -phase chronic myeloid leukemia: results from the 24-month follow up of the BELA trial. British J Haematology. 2015;168:69\u201381.","journal-title":"British J Haematology"},{"key":"689_CR37","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian TP, et al. Final 5 year results of DAISISONL the dasatinib versus imatinib study in treatment-naive chronic myelogenous leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"689_CR38","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglia G, Highes TP, et al. Long term benefits and risks of frontline nilotinib for chronic myelogenous leukemia in chronic phase 5-Year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044.","journal-title":"Leukemia"},{"key":"689_CR39","unstructured":"Ono T, Hino M, Matsumara I et al. Bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: final 3 year follow up results of a phase 2 study. Intl J Hematol 2002. Aug13."},{"key":"689_CR40","doi-asserted-by":"crossref","unstructured":"Kuwabara A, Babb A, Ibrahim A et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 2010: 116: 1014-1016 While a small study provides information about loss of response after stopping TKI therapy during pregnancy and outcomes after restarting therapy postpartum.","DOI":"10.1182\/blood-2010-04-280206"},{"key":"689_CR41","doi-asserted-by":"crossref","unstructured":"Chelysheva E, Turkina A, Polushkina E et al. Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia. Leukemia & Lymphoma 2018: 59: 733-738 Important data presented regarding placental transfer of TKIs.","DOI":"10.1080\/10428194.2017.1347929"},{"key":"689_CR42","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1634\/theoncologist.2019-0109","volume":"24","author":"X Dou","year":"2019","unstructured":"Dou X, Qin Y, Huang X, et al. Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Oncologist. 2019;24:e1141\u20137.","journal-title":"Oncologist"},{"key":"689_CR43","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","volume":"24","author":"P Ault","year":"2006","unstructured":"Ault P, Kantarjian H, O\u2019Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24:1204\u20138.","journal-title":"J Clin Oncol"},{"key":"689_CR44","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1080\/10428194.2018.1551533","volume":"60","author":"M Lasica","year":"2019","unstructured":"Lasica M, Willcox A, Burbury K, et al. The effect of tyrosine kinase interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leuk Lymphoma. 2019;60:1796\u2013802.","journal-title":"Leuk Lymphoma"},{"key":"689_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.jp.7211665","volume":"27","author":"MA Russell","year":"2007","unstructured":"Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007;27:241\u20133.","journal-title":"J Perinatol"},{"key":"689_CR46","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","volume":"29","author":"M Steinberg","year":"2007","unstructured":"Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia Chromosome positive acute lymphoblastic leukemia. Clin Ther. 2007;29:2289\u2013308.","journal-title":"Clin Ther"},{"key":"689_CR47","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","volume":"55","author":"R Abbas","year":"2017","unstructured":"Abbas R. Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin Pharmacokinet. 2017;55:1191\u2013204.","journal-title":"Clin Pharmacokinet"},{"key":"689_CR48","first-page":"187","volume":"111","author":"AM Zamah","year":"2008","unstructured":"Zamah AM, Mauro M, Druker BJ, et al. Will imatinib compromise reproductive capacity? Blood. 2008;111:187\u201394.","journal-title":"Blood"},{"key":"689_CR49","unstructured":"Deininger M, Shah NP, Altman J et al. Chronic myeloid leukemia, version 2.2020. NCCN practice guidelines in oncology. J Natl Compr Cancer Netw 2020: 19(10), 1385\u20131415."},{"key":"689_CR50","unstructured":"Baccarini M, Deininger MW, Rosti G t al. European LeukemiaNet recommendations for the management of treating chronic myeloid leukemia. Blood 2013; 122: (6): 872\u2013874."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-023-00689-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T03:21:56Z","timestamp":1678245716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-023-00689-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1007\/s11899-023-00689-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"19 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent."}}]}}